An interventional study of Percutaneous Coronary Intervention (PCI) and Diagnostic Imaging in Anterior STEMI, sponsored by Fundacio Privada Mon Clinic Barcelona. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-02.
Sponsored by Fundacio Privada Mon Clinic Barcelona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in ST Elevation Myocardial Infarction with a site in Spain — 4 open to participants now, 10 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Spain.
Among the 41 studies in ST Elevation Myocardial Infarction with a site in Spain, this one is the 26th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 with no phase, and was the 37th registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →4 of the 41 studies in ST Elevation Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:
Hospital General Universitario Santa Lucia · Sites in Spain
Ages 18+
Fundación Interhospitalaria para la Investigación Cardiovascular FIC · Sites in Spain
Ages 18+
Hospital Universitario La Fe · Sites in Spain
Ages 18+
Hospital Arnau de Vilanova · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 450 across the 27 interventional studies, 495 across the 14 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 41 have an industry lead sponsor. The 10 most frequent:
Fundacio Privada Mon Clinic Barcelona is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Fundacio Privada Mon Clinic Barcelona has 1 study filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in ST Elevation Myocardial Infarction with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT07780942Hospital General Universitario Santa LuciaSMARTwatch for the Diagnosis of ST-segment Elevation Myocardial Infarction in Patients With Chest Pain | 2027-02 |
| NCT07000266Fundacio Privada Mon Clinic BarcelonaThe RECOVERY Study: Using Supersaturated Oxygen Therapy To Treat Small Vessel Blockages After a Heart Attack | 2027-05-16 |
| NCT07444957Fundación Interhospitalaria para la Investigación Cardiovascular FICSafety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease | 2027-07-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in ST Elevation Myocardial Infarction with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study tests whether adding supersaturated oxygen (SSO₂) therapy to standard stent treatment can improve heart recovery after a major heart attack (anterior STEMI). Adults treated within 6 hours of symptoms will be randomly assigned to receive either standard care or standard care plus SSO₂. The goal is to see if SSO₂ reduces damage to small heart vessels. Heart function will be checked immediately, after one hour, and again at six months. Follow-up visits will track recovery for up to a year.
This is an investigator-initiated, post-market clinical investigation, interventional, prospective, randomized, controlled, open-label, monocenter study, in subjects with anterior STEMI with two parallel arms comparing the efficacy of SSO2 with standard PCI and standard PCI alone on reduction of microvascular resistances (Rµ)
Patients will be ≥ 18 years old and diagnosed with a first anterior STEMI requiring stent placement, symptoms duration of ≤ 6 hours and culprit lesion in the left anterior descending (LAD) artery with a TIMI (Thrombolysis In Myocardial Infarction) flow 0 or 1 without collateral circulation.
Patients who provide informed consent will be treated with primary PCI with stenting. Once the coronary blood flow is re-established, and after general and angiographic inclusion and exclusion criteria are confirmed, patients will be randomized and enrolled in the study.
A total number of 20 patients will be randomized (1:1) to SSO2 plus PCI arm or standard PCI control arm. Once randomized, SSO2 arm patients will receive SSO2 therapy inside the catheterization laboratory, meanwhile patients randomized in the standard arm will not receive further treatment beyond standard of care.
For both arms, coronary invasive measurements will be performed immediately and 60 minutes after coronary blood flow restoration and then at 6 months timepoint. Baseline clinical and procedural variables will be collected. There will be a clinical follow-up at 30 days ± 7 days, 6 months ± 1 month and 1 year ± 1 month after index event.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment group
Procedure: Percutaneous Coronary Intervention (PCI) · Diagnostic Test: Diagnostic Imaging · Device: Device Treatment · Procedure: Follow-up at 30 days · Procedure: Follow-up at 60 days · Procedure: Follow-up at 12 months
Control group
Procedure: Percutaneous Coronary Intervention (PCI) · Diagnostic Test: Diagnostic Imaging · Procedure: Follow-up at 30 days · Procedure: Follow-up at 60 days · Procedure: Follow-up at 12 months
Standard PCI intervention
Cardiac Magnetic Ressonance (CMR) and hospital discharge
SSO2 therapy
Remote (phone) follow-up at 30 days
In person follow-up at 60 days
Remote (phone) follow-up at 12 months
Effect of SSO2 on microvascular resistances (Rµ)
Superiority in % of patients without microvascular dysfunction (defined as microvascular resistance \>500 WU) of SSO2 arm versus standard of care (90% of patients with microvascular dysfunction in the control arm vs. 30% in the SSO2 arm)
Time frame: 60 minutes after primary PCI
Effect of SSO2 on absolute coronary flow (Q)
Absolute coronary flow (Q): difference in Q, between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.
Time frame: At 60 minutes and at 6 months after primary PCI
Effect of SSO2 on the index of microvascular resistance (IMR)
Microvascular resistances (Rµ): difference in (Rµ) between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.
Time frame: Within 5 minutes after primary PCI, at 60 minutes after primary PCI and at 6 months after primary PCI
Effect of SSO2 on the index of microvascular resistance (IMR)
Index of microvascular resistance (IMR): difference in IMR between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.
Time frame: Within 5 minutes after primary PCI, at 60 minutes after primary PCI and at 6 months after primary PCI
Effect of SSO2 on the coronary flow reserve (CFR)
Coronary flow reserve (CFR): difference in CFR between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.
Time frame: Within 5 minutes after primary PCI, at 60 minutes after PCI and at 6 months after primary PCI
Effect of SSO2 on the microvascular resistance reserve (MRR)
Microvascular resistance reserve (MRR): difference in MRR between the SSO2 arm and the standard PCI control arm, evaluated with invasive coronary measurement.
Time frame: Within 5 minutes after primary PCI, at 60 minutes after primary PCI and at 6 months after primary PCI
Effect of SSO2 on infarct size and microvascular obstruction at CMR
Quantification of infarct size as a percentage of left ventricular mass using late gadolinium enhancement (LGE) and assessment of microvascular obstruction (MVO) presence and extent.
Time frame: At CMR 3-5 days after primary PCI
Risk of predefined major cardiovascular adverse events (MACE) during treatment and follow-up
Time from randomization to the first occurrence of any event in the predefined MACE composite per patient.
Time frame: During treatment, during follow-up at 30 days, 60 days and 12 months follow-ups
Risk of predefined major cardiovascular adverse events (MACE) during treatment and follow-up
Per-patient rate of composite MACE events (first and subsequent)
Time frame: At at 30 days, 6 months and 1 year follow-ups after index PCI
Effect of SSO2 on ventricular remodeling
Proportion of patients with adverse ventricular remodeling, defined as a Δ ≥20% in end-diastolic volume (EDV) or a Δ ≥15% in end-systolic volume (ESV), with additional assessment of myocardial tissue characteristics using T2-weighted imaging and LGE.
Time frame: From baseline to follow-up CMR
Effect of SSO2 on left ventricular hypertrophy
Proportion of patients with left ventricular hypertrophy in the SSO2 therapy arm compared to the standard PCI control arm, as assessed by CMR. Left ventricular hypertrophy is considered for masses above 106.2 g/m2 for men and 84.6 g/m2 in women
Time frame: At CMR 3-5 days after primary PCI
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.
Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 23 months is below that.
Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Fundacio Privada Mon Clinic Barcelona